Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival

Department of Biochemistry and Molecular Biology, School of medicine, ShenZhen University, Shen Zhen, China.
Journal of Experimental & Clinical Cancer Research (Impact Factor: 3.27). 03/2012; 31(1):18. DOI: 10.1186/1756-9966-31-18
Source: PubMed

ABSTRACT Sex determining region Y (SRY)-related high mobility groupbox 9 (SOX9) is an important transcription factor required for development, which regulates the expression of target genes in the associated pathway. The aim of this study was to describe the expression of SOX9 in human non-small cell lung cancer (NSCLC) and to investigate the association between SOX9 expression and progression of NSCLC.
SOX9 protein and mRNA expression in normal human pneumonocytes, lung cancer cell lines, and eight pairs of matched lung cancer tissues and their adjacent normal lung tissues were detected by Western blotting and real-time reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemistry was used to determine SOX9 protein expression in 142 cases of histologically characterized NSCLC. Statistical analyses were applied to test for prognostic and diagnostic associations.
SOX9 in lung cancer cell lines was upregulated at both mRNA and protein levels, and SOX9 mRNA and protein were also elevated in NSCLC tissues compared with levels in corresponding adjacent non-cancerous lung tissues. Immunohistochemical analysis demonstrated a high expression of SOX9 in 74/142 (52.1%) paraffin-embedded archival lung cancer biopsies. Statistical analysis indicated that upregulation of SOX9 was significantly correlated with the histological stage of NSCLC (P=0.017) and that patients with a high SOX9 level exhibited a shorter survival time (P<0.001). Multivariate analysis illustrated that SOX9 upregulation might be an independent prognostic indicator for the survival of patients with NSCLC.
This work shows that SOX9 may serve as a novel and prognostic marker for NSCLC, and play a role during the development and progression of the disease.

  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: It has been more that 20 years since the first SOX genes were discovered. Twenty SOX genes have now been identified in mammals and classified into groups with respect to protein identity. SOX family genes code for transcription factors that either activate or repress lineage-specific genes during embryonic development. Furthermore, SOX genes are altered in human genetic syndromes and malignancies, highlighting their involvement in development. AREAS COVERED: This paper reviews the role of SOX genes in embryonic development and human diseases, and describe their involvement in human cancers and possible use in cancer therapeutics. EXPERT OPINION: Since most SOX genes behave as oncogenes in many human cancers, their targeting has great therapeutic potential. However, novel specific therapies such as those recently developed against growth factor receptors based on monoclonal antibodies, small inhibitors and even small interfering RNA strategies are difficult to implement for transcriptional factors. Novel strategies are being developed to overcome some of these obstacles. Alternative approaches could indirectly tackle altered SOX genes by exploiting the related molecular networks.
    Expert Opinion on Therapeutic Targets 07/2012; 16(9):903-19. DOI:10.1517/14728222.2012.709239 · 4.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the human genome forty-three different genes are found that encode proteins belonging to the family of the POK (POZ and Krüppel)/ZBTB (zinc finger and BTB) factors. Generally considered transcriptional repressors, several of these genes play fundamental roles in cell lineage fate decision in various tissues, programming specific tasks throughout the life of the organism. Here, we focus on LRF/Pokemon functions, probably one of the most exciting and yet enigmatic members of the POK/ZBTB family.
    Blood 02/2013; 121(15). DOI:10.1182/blood-2012-11-292037 · 10.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ALDH1+CD44+ cells are putative tumor-initiating cells (TICs) in head and neck squamous cell carcinomas (HNC). miR-145 regulates tumorigenicity in various cancers but the breadth of its mechanistic contributions and potential therapeutic applications are not completely known. Here we report that ALDH1+CD44+ HNC cells express reduced levels of miR145. SPONGE-mediated inhibition of miR-145 (Spg-miR145) was sufficient to drive tumor-initiating characteristics in non-TICs/ ALDH1-CD44-negative HNC cells. Mechanistic analyses identified SOX9 and ADAM17 as two novel miR145 targets relevant to this process. miR-145 expression repressed TICs in HNC in a manner associated with SOX9 interaction with the ADAM17 promoter, thereby activating ADAM17 expression. Notably, the SOX9/ADAM17 axis dominated the TIC inducing activity of miR-145. Either miR-145 suppression or ADAM17 overexpression in non-TICs/ALDH1-CD44- HNC cells increased expression and secretion of IL-6 and soluble-IL6 receptor (sIL6R). Conversely, conditioned medium from Spg-miR145-transfected non-TICs/ALDH1-CD44- HNC cells was sufficient to confer tumor-initiating properties in non-TICs/ALDH1-CD44- HNC and this effect could be abrogated by an IL-6 neutralizing antibody. We found that curcumin administration increased miR-145 promoter activity, thereby decreasing SOX9/ADAM17 expression and eliminating TICs in HNC cell populations. Delivery of lentivral-miR145 or orally administered curcumin blocked tumor progression in HNC-TICs in murine xenotransplant assays. Lastly, immunohistochemical analyses of patient specimens confirmed that an miR-145low/SOX9high/ADAM17high phenotype correlated with poor survival. Collectively, our results show how miR-145 targets the SOX9/ADAM17 axis to regulate TIC properties in HNC, and how altering this pathway may partly explain the anti-cancer effects of curcumin. By inhibiting IL-6 and sIL6R as downstream effector cytokines in this pathway, miR-145 appears to suppress a paracrine signaling pathway in the tumor microenvironment that is vital to maintain TICs in HNC.
    Cancer Research 04/2013; 73(11). DOI:10.1158/0008-5472.CAN-12-3840 · 9.28 Impact Factor
Show more

Preview (2 Sources)

Available from